TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11199313

Group type: EXPERIMENTAL
Intervention: Group 1 (1.8 m2, 220 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 3 (2.5 m2, 270 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Group 2 (2.2 m2, 290 ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study: 9700445

Group type: EXPERIMENTAL
Intervention: One of six different therapies
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Lemons and oranges
Number of subjects: 12
Study: 7871449

Group type: EXPERIMENTAL
Intervention: 250 mg ciprofloxacin
Number of subjects: 1180

Group type: EXPERIMENTAL
Intervention: 500 mg ciprofloxacin
Number of subjects: 1180

Group type: COMPARATOR
Intervention: Ceftriaxone, ampicillin/probenecid, amoxicillin/probenecid, spectinomycin
Number of subjects: 1180
Study: 3277008

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Ambulatory ECG monitoring (various durations)
Number of subjects: 3837

Group type: COMPARATOR
Intervention: Ambulatory ECG monitoring (24 hours)
Number of subjects: 3837
Study: 31904566

Group type: EXPERIMENTAL
Intervention: HPV vaccination (bivalent)
Number of subjects: 7372
Study: 30939198

Group type: EXPERIMENTAL
Intervention: iMVCquad-HHD (fixed handheld dynamometer)
Number of subjects: 65
Study: 29129443

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (15 mg/kg intravenously every 21 days for 1 year)
Number of subjects: 1501

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 1501

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 1501
Study: 26852501

Group type: EXPERIMENTAL
Intervention: Resonance-microwave therapy with the Akvaton-02 apparatus
Number of subjects: 50

Group type: COMPARATOR
Intervention: Basic drug therapy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Resonance-microwave therapy
Number of subjects: 50
Study: 23985435

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 1.5% arginine and 1450 ppm fluoride
Number of subjects: 438

Group type: COMPARATOR
Intervention: Positive control dentifrice containing 1450 ppm fluoride
Number of subjects: 438

Group type: COMPARATOR
Intervention: Negative control dentifrice without arginine and fluoride
Number of subjects: 438
Study: 21483892

Group type: EXPERIMENTAL
Intervention: Bio‐Oss Collagen augmentation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Unaugmented extraction sockets
Number of subjects: 25
Study: 18328638

Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy (MET)
Number of subjects: 461

Group type: COMPARATOR
Intervention: Drug Counseling-as-usual
Number of subjects: 461
Study: 16907900

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.5 mg, t.d.s for 7 days)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (n = 5)
Number of subjects: 13
Study: 12737754

Group type: EXPERIMENTAL
Intervention: Atovaquone/proguanil
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 30000
Study: 10669281

Group type: EXPERIMENTAL
Intervention: Ephedrine 0.5 mg/kg i.m.
Number of subjects: 109

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 109
Study: 9055768

Group type: EXPERIMENTAL
Intervention: Ultrasound examination
Number of subjects: 240

Group type: COMPARATOR
Intervention: Initial chest radiograph
Number of subjects: 240
Study: 30125891

Group type: EXPERIMENTAL
Intervention: Customized training (department-specific orientation video, locally made posters, and didactic sessions)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard training (videos, posters, and didactic sessions from the World Health Organization)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Customized training
Number of subjects: 244

Group type: COMPARATOR
Intervention: Standard training
Number of subjects: 244
Study: 26970957

Group type: EXPERIMENTAL
Intervention: Resistance and Endurance exercise After ChemoTherapy (REACT)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition Routine Improving Cancer Health (ENRICH)
Number of subjects: 574

Group type: EXPERIMENTAL
Intervention: Move More for Life (MM4L)
Number of subjects: 574
Study: 24581015

Group type: EXPERIMENTAL
Intervention: Human Patient Simulation (HPS) education
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no HPS education)
Number of subjects: 30
Study: 22707519

Group type: EXPERIMENTAL
Intervention: Manual therapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Usual care by general practitioner
Number of subjects: 186
Study: 19595042

Group type: EXPERIMENTAL
Intervention: Anterior decompression methods (discectomy of one to three segments, subtotal vertebrectomy of one to two segments, discectomy plus subtotal vertebrectomy)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: Posterior decompression methods (posterior expansive single open door laminoplasty and other operation types)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Age groups and course groups
Number of subjects: 263
Study: 16785738

Group type: EXPERIMENTAL
Intervention: Prednisolone alone (1 mg/kg BW/day)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of prednisolone (0.5 mg/kg BW/day) with azathioprine (2 mg/kg BW/day) or cyclosporine (3 mg/kg BW/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: No immunosuppressive drugs (Control group)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Prednisolone alone
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Combination of lower prednisolone dose with azathioprine and cyclosporin
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall treated group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 51
Study: 14718058

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching gel for 8 hours per day for 1 week (Group 2)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate treatment (Group 3)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Immersion in artificial saliva for 1 week before restoration (Group 4)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Self-etching adhesive system and resin composite restoration (Group 1)
Number of subjects: 48
Study: 11723415

Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone‐acetate (MPA) (10 mg/day) with continuous transdermal estradiol (TE) (50 microg/day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Vaginal danazol (200 mg/day) with continuous TE
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Estrogen alone (TE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups (1, 2, 3)
Number of subjects: 40
Study: 9469532

Group type: EXPERIMENTAL
Intervention: Intranasal inflammation induced by cold air (145 ml/s) with varying humidity and temperature
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Gaseous CO2 applied to the left nostril (36 stimuli of 200 ms; 65% v/v CO2; interstimulus interval 30 s)
Number of subjects: 20
Study: 8188800

Group type: EXPERIMENTAL
Intervention: Training on clue words
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 3540139

Group type: EXPERIMENTAL
Intervention: B subunit‐killed whole cell (BS‐WC) cholera vaccine
Number of subjects: 1257

Group type: EXPERIMENTAL
Intervention: Killed whole cell‐only (WC) cholera vaccine
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Killed Escherichia coli strain K12 placebo
Number of subjects: 1257

Group type: COMPARATOR
Intervention: Control agent
Number of subjects: 1257
Study: 29232316

Group type: EXPERIMENTAL
Intervention: PRIME
Number of subjects: 107

Group type: COMPARATOR
Intervention: AT
Number of subjects: 107
Study: 27939054

Group type: EXPERIMENTAL
Intervention: DTaP-IPV-HB-PRP-T vaccine co-administered with MenC vaccine (Group 1; n=175)
Number of subjects: 350

Group type: COMPARATOR
Intervention: DTaP-IPV-HB-PRP-T vaccine without MenC vaccine (Group 2; n=175)
Number of subjects: 350
Study: 25677790

Group type: COMPARATOR
Intervention: Protocol A: Conventional 120-kVp protocol with standard CM dose (280 mg iodine/kg body weight)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Protocol B: 80-kVp with 25% CM dose reduction (210 mg iodine/kg body weight)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Protocol C: 80-kVp with 50% CM dose reduction (140 mg iodine/kg body weight)
Number of subjects: 90
Study: 23127806

Group type: EXPERIMENTAL
Intervention: Polyethylene glycol (PEG)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 21440942

Group type: EXPERIMENTAL
Intervention: 1 or 4 mg intravitreal triamcinolone
Number of subjects: 209

Group type: COMPARATOR
Intervention: Standard care (observation or grid photocoagulation)
Number of subjects: 209
Study: 19004201

Group type: EXPERIMENTAL
Intervention: Yiweikang Capsule
Number of subjects: 67

Group type: COMPARATOR
Intervention: Wenweishu Capsule
Number of subjects: 67
Study: 17154645

Group type: COMPARATOR
Intervention: RIX4414 (Rotarix™)
Number of subjects: 63225
Study: 15134313

Group type: EXPERIMENTAL
Intervention: Parent Management Training (PMT)
Number of subjects: 238
Study: 10891016

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program (avoidance of house dust mite and pet allergens, environmental tobacco smoke, encouragement of breastfeeding, supplementation with partially hydrolyzed formula)
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 545

Group type: EXPERIMENTAL
Intervention: Multifaceted intervention program
Number of subjects: 545

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 545
Study: 9291901

Group type: EXPERIMENTAL
Intervention: Chronotherapy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Constant-rate infusion
Number of subjects: 186
Study: 7508773

Group type: EXPERIMENTAL
Intervention: Interferon at 1.5 x 10(6) U three times per week for 1 year
Number of subjects: 88

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 88
Study: 3525369

Group type: EXPERIMENTAL
Intervention: Sclerotherapy plus oral propranolol (dose sufficient to reduce resting pulse rate by 25%)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Sclerotherapy alone
Number of subjects: 53
Study: 31294749

Group type: EXPERIMENTAL
Intervention: Pembrolizumab (200 mg/kg every 3 weeks) after 3 doses of 8 Gy stereotactic body radiotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Pembrolizumab (200 mg/kg every 3 weeks) alone (control arm)
Number of subjects: 92
Study: 28580293

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 100
Study: 25822236

Group type: EXPERIMENTAL
Intervention: Booster Plus (ABP visible during training and testing)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Booster Alone (ABP visible only during training, not testing)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control (testing, no intervention)
Number of subjects: 36
Study: 23434449

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride (0.05 mg/kg IV 10 minutes before cardiopulmonary bypass)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (saline injection)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Number of subjects: 40
Study: 21277510

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 19876674

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) with varied administration of exposure
Number of subjects: 369

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 369
Study: 16990724

Group type: EXPERIMENTAL
Intervention: Postoperative motion with a mobile hinge and a motion protocol
Number of subjects: 55

Group type: COMPARATOR
Intervention: Postoperative nonmotion with a locked hinge
Number of subjects: 55
Study: 14734877

Group type: EXPERIMENTAL
Intervention: R‐ORS
Number of subjects: 189

Group type: COMPARATOR
Intervention: G‐ORS
Number of subjects: 189
Study: 11376225

Group type: EXPERIMENTAL
Intervention: Graphically enhanced consent disclosure form
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Presence of a third-party facilitator
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Iterative feedback during consent process
Number of subjects: 241

Group type: COMPARATOR
Intervention: Standard dense text consent disclosure form
Number of subjects: 241

Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Schizophrenia group
Number of subjects: 241
Study: 9207282

Group type: EXPERIMENTAL
Intervention: Diclofenac (75 mg, 3 mL intramuscular injection)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo (3 mL saline, intramuscular injection)
Number of subjects: 53
Study: 8272262

Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside, administered intravenously at a dose of 100 mg, 6 days a week for 2 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GM-1 ganglioside
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3619096

Group type: COMPARATOR
Intervention: Bupivacaine plus 1 ml normal saline (Group 1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.2 mg epinephrine (Group 3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.3 mg epinephrine (Group 4)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.4 mg epinephrine (Group 5)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus 0.5 mg epinephrine (Group 6)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Bupivacaine plus increasing dosages of epinephrine (Groups 2-6)
Number of subjects: 96
Study: 30719932

Group type: EXPERIMENTAL
Intervention: Resin infiltration
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Microabrasion
Number of subjects: 20
Study: 27584137

Group type: EXPERIMENTAL
Intervention: Low-activity foot (LA)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-activity energy-storage-and-return (ESAR) foot
Number of subjects: 28
Study: 26412178

Group type: EXPERIMENTAL
Intervention: High-volume hemofiltration (HVHF)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard-volume hemofiltration (SVHF)
Number of subjects: 36
Study: 22791234

Group type: EXPERIMENTAL
Intervention: Bortezomib and Irinotecan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan added at time of progression on bortezomib
Number of subjects: 0
Study: 21054506

Group type: EXPERIMENTAL
Intervention: Tissue Conditioner (TC)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Autopolymerising Hard Reline Material (AHRM)
Number of subjects: 44
Study: 19117033

Group type: EXPERIMENTAL
Intervention: Oral calcium (3 g/day) plus vitamin D (1 mg/day) (Group A, n=49)
Number of subjects: 197

Group type: EXPERIMENTAL
Intervention: Calcium alone (Group B, n=49)
Number of subjects: 197

Group type: COMPARATOR
Intervention: No supplements (Group C, n=50)
Number of subjects: 197
Study: 17522475

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) low dose (50 mg/week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) medium dose (100 mg/week)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (ND) high dose (200 mg/week)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control (non-randomized)
Number of subjects: 54
Study: 15333268

Group type: EXPERIMENTAL
Intervention: Specific language screening conducted at 18 and 24 months
Number of subjects: 10355

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 10355
Study: 12193356

Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment in a clinical trial
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Thrombolysis treatment if shown effective
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Consent to enter the planned trial
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Revised trial materials
Number of subjects: 54
Study: 9539641

Group type: EXPERIMENTAL
Intervention: McDonald's Quarter Pounder, french fries, and chocolate shake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: McDonald's Sausage Biscuit with Egg, cheese, raw onion, and chocolate milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wendy's Chili and red wine
Number of subjects: 0
Study: 7973772

Group type: EXPERIMENTAL
Intervention: Cisplatin/5-fluorouracil/leucovorin (PFL) combination
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vinorelbine (Navelbine) added to PFL
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vinorelbine at 20 mg/m2/d
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Vinorelbine at 25 mg/m2/d
Number of subjects: 16
Study: 2700878

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (O.C.)
Number of subjects: 1044

Group type: COMPARATOR
Intervention: Control (non-O.C. users)
Number of subjects: 1044
Study: 786260

Group type: EXPERIMENTAL
Intervention: PLP 100‐127
Number of subjects: 30

Group type: COMPARATOR
Intervention: Nitrazepam
Number of subjects: 30
Study: 31580800

Group type: EXPERIMENTAL
Intervention: Multitarget therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Cyclophosphamide (CYC)
Number of subjects: 11
Study: 28382797

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 343

Group type: COMPARATOR
Intervention: Radiotherapy (RT)
Number of subjects: 343
Study: 25790066

Group type: EXPERIMENTAL
Intervention: Endotoxaemia induced by lipopolysaccharide (LPS) 0.3 ng/kg b.w. at 12:00 h (day visit)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Endotoxaemia induced by lipopolysaccharide (LPS) 0.3 ng/kg b.w. at 24:00 h (night visit)
Number of subjects: 12
Study: 23053123

Group type: EXPERIMENTAL
Intervention: Aerobic training for 6 weeks
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 13
Study: 21150602

Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor (TNF) and melphalan based isolated limb perfusion (TM-ILP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Melphalan only based isolated limb perfusion (M-ILP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isolated limb infusion (ILI) with melphalan and actinimycin D
Number of subjects: 0
Study: 19567091

Group type: EXPERIMENTAL
Intervention: 8 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 7 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: 6 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 5 ml of anesthetic mixture (0.75% ropivacaine and 2% lidocaine)
Number of subjects: 160
Study: 16389160

Group type: EXPERIMENTAL
Intervention: Quinapril (20 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Losartan (100 mg/day)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Quinapril plus Losartan (20 mg/day + 100 mg/day)
Number of subjects: 62
Study: 15285927

Group type: EXPERIMENTAL
Intervention: (125)I (144 Gy, TG-43)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: (103)Pd (125 Gy, NIST-99)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: (125)I
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: (103)Pd
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: (125)I and (103)Pd
Number of subjects: 122
Study: 11070965

Group type: EXPERIMENTAL
Intervention: Preemptive intravenous morphine (0.15 mg.kg‐1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Preemptive epidural morphine (75 micrograms.kg‐1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (intravenous saline)
Number of subjects: 60
Study: 9061114

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of vecuronium administered 5 minutes prior to inflation of a pneumatic tourniquet (Group I)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg of vecuronium administered after inflation of the tourniquet (Group II)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neostigmine 30‐40 micrograms/kg i.v. administered to all subjects in both groups
Number of subjects: 16
Study: 8112641

Group type: EXPERIMENTAL
Intervention: Closure including subcutaneous retention sutures
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard wound closure
Number of subjects: 80
Study: 31583603

Group type: EXPERIMENTAL
Intervention: Younger boy (ages 12, 15)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Older man (ages 18, 21, 24)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Mothers
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Fathers
Number of subjects: 360
Study: 29783674

Group type: EXPERIMENTAL
Intervention: Korean male smokers
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Korean smokers
Number of subjects: 300
Study: 27128564

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 801

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 801
Study: 24452645

Group type: EXPERIMENTAL
Intervention: Active rTMS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Motor Cortex Stimulation (MCS)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Preoperative rTMS
Number of subjects: 20
Study: 21349756

Group type: EXPERIMENTAL
Intervention: Pédimed(®) cream applied twice daily for 4 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo applied twice daily for 4 weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Pédimed(®) cream
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 15932664

Group type: EXPERIMENTAL
Intervention: Nadroparin (0.075 ml/10 kg)
Number of subjects: 98
Study: 12172535

Group type: COMPARATOR
Intervention: Benzathine penicillin G (2.4 million units, intramuscular injection)
Number of subjects: 60